Patents by Inventor Ricky Gaston
Ricky Gaston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070112067Abstract: The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione.Type: ApplicationFiled: December 19, 2006Publication date: May 17, 2007Applicant: NitroMed, Inc.Inventors: David Garvey, Ricky Gaston, L. Letts, Inigo de Tejada, Sang Tam, Manuel Worcel
-
Publication number: 20070037821Abstract: The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic acid compound, and, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent.Type: ApplicationFiled: September 27, 2004Publication date: February 15, 2007Applicant: NITROMED, INC.Inventors: David Garvey, Richard Earl, Malko Ezawa, Xinqin Fang, Ricky Gaston, Subhash Khanapure, Chia-En Lin, Ramani Ranatunga, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20070010571Abstract: The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at,least one cardiovascular compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy.Type: ApplicationFiled: August 20, 2004Publication date: January 11, 2007Applicant: NITROMED, INC.Inventors: David Garvey, L. Letts, Manuel Worcel, Ricky Gaston
-
Publication number: 20060189603Abstract: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia.Type: ApplicationFiled: February 24, 2006Publication date: August 24, 2006Applicant: NitroMed, Inc.Inventors: David Garvey, L. Letts, Richard Earl, Maiko Ezawa, Xinqin Fang, Ricky Gaston, Subhash Khanapure, Chia-En Lin, Ramani Ranatunge, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20060009431Abstract: The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix.Type: ApplicationFiled: September 9, 2005Publication date: January 12, 2006Applicant: NitroMed, Inc.Inventors: Richard Earl, David Garvey, Ricky Gaston, Chia-En Lin, Ramani Ranatunge, Stewart Richardson, Cheri Stevenson
-
Publication number: 20050222243Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: ApplicationFiled: May 23, 2005Publication date: October 6, 2005Applicant: NitroMed, Inc.Inventors: Richard Earl, Maiko Ezawa, Xinqin Fang, David Garvey, Ricky Gaston, Subhash Khanapure, L. Gordon Letts, Chia-En Lin, Ramani Ranatunga, Stewart Richardson, Joseph Schroeder, Cheri Stevenson, Shiow-Jyi Wey
-
Publication number: 20050187222Abstract: The present invention describes novel nitrosated and/or nitrosylated ?-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated ?-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one ?-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents.Type: ApplicationFiled: April 20, 2005Publication date: August 25, 2005Applicant: NitroMed, Inc.Inventors: David Garvey, Inigo De Tejada, Ricky Gaston, Subhash Khanapure, Tatiana Shelekhin, Tiansheng Wang
-
Publication number: 20050059665Abstract: The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal anti-inflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pyType: ApplicationFiled: October 21, 2004Publication date: March 17, 2005Applicant: NitroMed, Inc.Inventors: Subhash Khanapure, David Garvey, Richard Earl, Maiko Ezawa, Xinqin Fang, Ricky Gaston